Elske Vrieze1, Koen Demyttenaere2, Ronny Bruffaerts2, Dirk Hermans3, Diego A Pizzagalli4, Pascal Sienaert5, Titia Hompes2, Peter de Boer6, Mark Schmidt6, Stephan Claes2. 1. Department of Psychiatry, University Psychiatric Center, Campus Leuven, Leuven, Belgium. Electronic address: elske.vrieze@uc-kortenberg.be. 2. Department of Psychiatry, University Psychiatric Center, Campus Leuven, Leuven, Belgium. 3. Department of Psychology, KU Leuven, Leuven, Belgium. 4. Department of Psychiatry, Harvard Medical School, Belmont, MA, USA. 5. Department of Psychiatry, University Psychiatric Center, Campus Kortenberg 3070, Belgium. 6. Janssen Research and Development, Division of Janssen Pharmaceutica, NV, Beerse, Belgium.
Abstract
BACKGROUND: Major depressive disorder (MDD) is a heterogeneous disease. More homogeneous psycho(patho)logical dimensions would facilitate MDD research as well as clinical practice. The first aim of this study was to find potential dimensions within a broad psychopathological assessment in depressed patients. Second, we aimed at examining how these dimensions predicted course in MDD. METHODS: Ten psychopathological variables were assessed in 75 MDD inpatients. Factor and regression analyses assessed putative relations between psychopathological factors and depression severity and outcome after 8 weeks of treatment. RESULTS: A 3-factor model (eigenvalue: 54.4%) was found, representing a psychomotor change, anhedonia and negative affect factor. Anhedonia and negative affect predicted depression severity (R(2)=0.37, F=20.86, p<0.0001). Anhedonia predicted non-response (OR 6.00, CI 1.46-24.59) and both negative affect (OR 5.69, CI 1.19-27.20) and anhedonia predicted non-remission (OR 9.28, CI 1.85-46.51). LIMITATIONS: The sample size of the study was relatively modest, limiting the number of variables included in the analysis. CONCLUSIONS: Results confirm that psychomotor change, anhedonia and negative affect are key MDD dimensions, two of which are related to treatment outcome.
BACKGROUND:Major depressive disorder (MDD) is a heterogeneous disease. More homogeneous psycho(patho)logical dimensions would facilitate MDD research as well as clinical practice. The first aim of this study was to find potential dimensions within a broad psychopathological assessment in depressedpatients. Second, we aimed at examining how these dimensions predicted course in MDD. METHODS: Ten psychopathological variables were assessed in 75 MDD inpatients. Factor and regression analyses assessed putative relations between psychopathological factors and depression severity and outcome after 8 weeks of treatment. RESULTS: A 3-factor model (eigenvalue: 54.4%) was found, representing a psychomotor change, anhedonia and negative affect factor. Anhedonia and negative affect predicted depression severity (R(2)=0.37, F=20.86, p<0.0001). Anhedonia predicted non-response (OR 6.00, CI 1.46-24.59) and both negative affect (OR 5.69, CI 1.19-27.20) and anhedonia predicted non-remission (OR 9.28, CI 1.85-46.51). LIMITATIONS: The sample size of the study was relatively modest, limiting the number of variables included in the analysis. CONCLUSIONS: Results confirm that psychomotor change, anhedonia and negative affect are key MDD dimensions, two of which are related to treatment outcome.
Authors: Anne T M Konkle; Stephanie L Baker; Amanda C Kentner; Lisa Santa-Maria Barbagallo; Zul Merali; Catherine Bielajew Journal: Brain Res Date: 2003-12-05 Impact factor: 3.252
Authors: Kelly Serafini; Bo Malin-Mayor; Charla Nich; Karen Hunkele; Kathleen M Carroll Journal: Am J Drug Alcohol Abuse Date: 2016-02-23 Impact factor: 3.829
Authors: Marie Eikemo; Philipp P Lobmaier; Mads L Pedersen; Nikolaj Kunøe; Anna Maria Matziorinis; Siri Leknes; Monica Sarfi Journal: Neuropsychopharmacology Date: 2019-03-31 Impact factor: 7.853
Authors: Robert Suchting; Jessica N Vincent; Scott D Lane; Charles E Green; Joy M Schmitz; Margaret C Wardle Journal: Drug Alcohol Depend Date: 2018-11-15 Impact factor: 4.492
Authors: Joanna E Szczepanik; Maura L Furey; Allison C Nugent; Ioline D Henter; Carlos A Zarate; Carl W Lejuez Journal: Behav Res Ther Date: 2017-08-03
Authors: Elaine Setiawan; Alan A Wilson; Romina Mizrahi; Pablo M Rusjan; Laura Miler; Grazyna Rajkowska; Ivonne Suridjan; James L Kennedy; P Vivien Rekkas; Sylvain Houle; Jeffrey H Meyer Journal: JAMA Psychiatry Date: 2015-03 Impact factor: 21.596
Authors: Sarah M Szymkowicz; Vonetta M Dotson; Jacob D Jones; Michael S Okun; Dawn Bowers Journal: J Int Neuropsychol Soc Date: 2017-10-16 Impact factor: 2.892
Authors: Joanna E Szczepanik; Jessica L Reed; Allison C Nugent; Elizabeth D Ballard; Jennifer W Evans; Carl W Lejuez; Carlos A Zarate Journal: Brain Imaging Behav Date: 2019-12 Impact factor: 3.978
Authors: Emma E M Knowles; Samuel R Mathias; Godfrey D Pearlson; Jennifer Barrett; Josephine Mollon; Dominique Denbow; Katrina Aberzik; Molly Zatony; David C Glahn Journal: Schizophr Res Date: 2018-10-26 Impact factor: 4.939